Crystal Davison, APRN
Family · Lees Summit, MONPI 1467728089
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 558 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,591, more than ten times the $401 reported in 2021. Among family clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 558 payments — averaging $28.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Jazz Pharmaceuticals Inc.$2K
- Inspire Medical Systems, Inc.$2K
- Harmony Biosciences LLC$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$1K
- plus $6K from 40 others
What the payments were for
- Consulting fees$1501%
- Travel & lodging$9336%
- Food & beverage$14,20191%
- Education$4003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,684 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sodium Oxybate | 11 | $210,175 |
| WakixPitolisant Hcl | 12 | $182,894 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $33,020 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $16,653 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $9,141 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,359 |
| Armodafinil | 35 | $4,956 |
| Modafinil | 38 | $3,376 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $1,525 |
| Zaleplon | 33 | $595 |
| Eszopiclone | 32 | $556 |
| Zolpidem Tartrate | 45 | $475 |
| Fluticasone Propionate | 22 | $430 |
| Ipratropium Bromide | 16 | $418 |
| Levocetirizine Dihydrochloride | 24 | $314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $1,490 | $182,89412 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $820 | $49,67372 claims |
| Boehringer IngelheimStiolto Respimat | $836 | $9,14114 claims |
| AstraZenecaBreztri Aerosphere | $2,173 | $8,35913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Lees Summit
- Tamera WolfLees Summit$215K
- Christine HuntLees Summit$12K
- Shayla SandersKansas City$306K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.